Probiotic efficacy of Bacillus amyloliquefaciens TL106 from Tibetan pigs in metabolic syndrome: modulation of gut microbiota and metabolic in sows and suckling piglets - PubMed
4 hours ago
- #probiotics
- #metabolic-syndrome
- #gut-microbiota
- Bacillus amyloliquefaciens TL106 from Tibetan pigs was evaluated for its probiotic efficacy in alleviating metabolic syndrome in sows and improving piglet growth.
- A 43-day trial showed that dietary TL106 improved digestibility of crude fiber (+12.5%) and crude fat (+9.3%), reduced inflammatory cytokines (IL-1β by 34%, TNF-α by 28%), and enhanced antioxidant enzymes and immunoglobulins.
- TL106 supplementation led to better litter performance, including a significant reduction in diarrhea and heavier piglets at 21 days (+15%).
- Multi-omics analysis revealed increased gut microbiota diversity in piglets, with enrichment of butyrate-producing bacteria like Ruminococcus and Butyricicoccus, and activation of metabolic pathways related to histidine and ABC transporters.
- In sows, TL106 favored pathways for amino acid biosynthesis, lipid utilization, and steroidogenesis, improving metabolic health.
- The study concludes that Bacillus amyloliquefaciens TL106 is effective in managing metabolic syndrome in sows and enhancing neonatal development by modulating gut microbiota and host metabolism.